Serial measurements of lymphocytes, D-dimer, LDH, and CRP do not improve the ability to predict COVID-19 adverse outcomes.

Jorge Pulido-ArenasDaniela Saa-GonzálezOscar Mauricio Muñoz-Velandia Alejandra Cañas-Arboleda

Published in: The Journal of international medical research (2023)

Measuring serum risk markers upon hospital admission can be used to evaluate risk of adverse outcomes in hospitalized patients with COVID-19. Repeating these measurements at 48 to 72 hours does not improve discriminatory ability.

Keyphrases

coronavirus disease
sars cov
emergency department
healthcare
peripheral blood
acute care
adverse drug